Profound Medical Corp.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-42.6M | $-27.8M | $-28.3M | $-28.7M | $-30.7M | $-21.6M | $-15.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $373.0K | $707.0K | $727.0K | $672.0K | $518.0K | $352.0K | $394.0K |
| Amortization | $187.0K | $229.0K | $202.0K | $704.0K | $1.0M | $881.0K | $856.0K |
| Stock-Based Compensation | $5.5M | $2.6M | $3.4M | $4.2M | $7.2M | $3.0M | $1.3M |
| Net Cash from Operating Activities | $-38.2M | $-23.5M | $-22.6M | $-25.8M | $-22.4M | $-20.6M | $-15.1M |
| Investing Activities | |||||||
| Capital Expenditures | $176.0K | — | — | — | $32.0K | — | — |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-242.0K | — | — | — | $-593.0K | $-350.0K | $-189.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $41.1M | $54.7M | $1.8M | $7.0M | $5.9M | $87.4M | $6.6M |
| Net Change in Cash | — | — | — | — | — | $66.5M | $-8.6M |
| Free Cash Flow | $-38.4M | — | — | — | $-22.4M | — | — |